Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,198,624
  • Shares Outstanding, K 2,532,726
  • Annual Sales, $ 50,266 M
  • Annual Income, $ 5,844 M
  • 60-Month Beta 0.60
  • Price/Sales 2.98
  • Price/Cash Flow 8.56
  • Price/Book 1.76
Trade SNY with:

Options Overview Details

View History
  • Implied Volatility 30.80% ( -0.48%)
  • Historical Volatility 16.34%
  • IV Percentile 88%
  • IV Rank 60.47%
  • IV High 39.81% on 04/24/24
  • IV Low 17.02% on 03/11/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 510
  • Volume Avg (30-Day) 1,910
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 44,697
  • Open Int (30-Day) 46,098

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.36
  • Number of Estimates 5
  • High Estimate 1.40
  • Low Estimate 1.30
  • Prior Year 1.39
  • Growth Rate Est. (year over year) -2.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.61 +0.64%
on 10/11/24
58.29 -5.72%
on 09/19/24
-2.50 (-4.35%)
since 09/11/24
3-Month
49.76 +10.45%
on 07/17/24
58.97 -6.80%
on 09/04/24
+3.75 (+7.32%)
since 07/11/24
52-Week
42.63 +28.92%
on 10/27/23
58.97 -6.80%
on 09/04/24
+0.17 (+0.31%)
since 10/11/23

Most Recent Stories

More News
Regeneron Gains 13.5% Year to date: How to Play the Stock?

Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.The stock has outperformed the sector during this timeframe but underperformed...

BAYRY : 7.2500 (-1.41%)
REGN : 1,015.67 (+1.67%)
RHHBY : 39.1800 (+0.80%)
SNY : 54.96 (+0.35%)
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

For Immediate ReleaseChicago, IL – October 8, 2024 – Today, Zacks Equity Research Eli Lilly LLY, AstraZeneca AZN, Pfizer PFE, Sanofi SNY and Bayer BAYRY.Industry: Big PharmaLink: https://www.zacks.com/commentary/2346520/5-large-drug-stocks-to-watch-from-a-thriving-industryThe...

BAYRY : 7.2500 (-1.41%)
AZN : 77.35 (+0.62%)
LLY : 932.06 (+2.35%)
PFE : 29.16 (-0.61%)
SNY : 54.96 (+0.35%)
5 Large Drug Stocks to Watch From a Thriving Industry

The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and...

BAYRY : 7.2500 (-1.41%)
AZN : 77.35 (+0.62%)
LLY : 932.06 (+2.35%)
PFE : 29.16 (-0.61%)
SNY : 54.96 (+0.35%)
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

STLA : 13.01 (-2.18%)
SOUN : 4.91 (+1.45%)
RXRX : 6.62 (+7.12%)
RHHBY : 39.1800 (+0.80%)
SNY : 54.96 (+0.35%)
1 AI Biotech Stock That Just Scored a Major Milestone

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

BAYZF : 28.8100 (-1.17%)
RXRX : 6.62 (+7.12%)
EXAI : 4.97 (+5.52%)
SNY : 54.96 (+0.35%)
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More

This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication. The FDA also granted priority review designation to AstraZeneca’s AZN label...

AZN : 77.35 (+0.62%)
LLY : 932.06 (+2.35%)
ABBV : 194.19 (-0.08%)
REGN : 1,015.67 (+1.67%)
SNY : 54.96 (+0.35%)
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant

Eli Lilly and Company LLY announced a significant $4.5 billion investment for the establishment of the Lilly Medicine Foundry in Indiana to advance drug production and innovation. This facility will enable...

AZN : 77.35 (+0.62%)
NVO : 120.04 (+2.14%)
LLY : 932.06 (+2.35%)
SNY : 54.96 (+0.35%)
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the United States....

LLY : 932.06 (+2.35%)
REGN : 1,015.67 (+1.67%)
PFE : 29.16 (-0.61%)
SNY : 54.96 (+0.35%)
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why

Shares of Amgen AMGN fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the autoimmune disease space. While the studies did meet their respective primary endpoints,...

REGN : 1,015.67 (+1.67%)
ARGX : 536.70 (+1.79%)
AMGN : 328.35 (+2.29%)
SNY : 54.96 (+0.35%)
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health

The drug and biotech sector has outperformed the broader equity market this year, backed by the launch of promising new medicines, pipeline successes and an increase in merger and acquisition (M&A) activity....

BAYRY : 7.2500 (-1.41%)
AZN : 77.35 (+0.62%)
LLY : 932.06 (+2.35%)
PFE : 29.16 (-0.61%)
SNY : 54.96 (+0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 55.53
2nd Resistance Point 55.28
1st Resistance Point 55.12
Last Price 54.96
1st Support Level 54.70
2nd Support Level 54.45
3rd Support Level 54.29

See More

52-Week High 58.97
Last Price 54.96
Fibonacci 61.8% 52.73
Fibonacci 50% 50.80
Fibonacci 38.2% 48.87
52-Week Low 42.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar